Amount Raised
$18 Million
Round Type
Funding Round
New YorkOtherBiotechnologySoftwareHealth CareDescription
Nucleus Genomics, a next-generation consumer genetic testing and analysis company, has raised $14 million in a new funding round led by Alexis Ohanian's Seven Seven Six. The NYC-based company, founded by Kian Sadeghi, is building a DTC genetic testing platform that provides innovative genetic risk and disposition score analyses on an extensive number of diseases and traits by leveraging whole-genome sequencing (WGS). The company also believes in maximal data ownership and liberty by providing its users total autonomy over their genetic data.
Quick answer
Nucleus Genomics raised $18 Million in a Funding Round round, dated July 14, 2022. Nucleus Genomics is based in New York, New York, United States.
- How much did Nucleus Genomics raise?
- Nucleus Genomics raised $18 Million in a Funding Round round on July 14, 2022.
- What does Nucleus Genomics do?
- Nucleus is an advanced DNA health test that takes the guesswork out of healthcare, whether it’s knowing your risk for cancer or planning for a healthy family.
- Where is Nucleus Genomics based and how big is it?
- Nucleus Genomics is based in New York, New York, United States. Fundz records about 31 employees.
- Who are the decision-makers at Nucleus Genomics?
- Fundz holds 1 contact at Nucleus Genomics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Software around the same time
Companies in the same sectors as Nucleus Genomics that raised within 45 days of this round, from Fundz verified event records.
- FundamentalVR raised $20M (Funding Round) on August 11, 2022.
- Biofourmis raised an undisclosed amount (Series D) on August 10, 2022.
- Sympatic raised an undisclosed amount (Pre-Seed) on August 4, 2022.
- Medical Microinstruments raised $75M (Funding Round) on July 20, 2022.
- PMGC Holdings Inc. raised $2.1M (Seed) on July 15, 2022.
- My Ome raised $23M (Series B) on June 21, 2022.
Who to call at Nucleus Genomics, and when
A new round usually means Nucleus Genomics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Nucleus Genomics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nucleus Genomics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nucleus Genomics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nucleus Genomics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Nucleus Genomics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.